openPR Logo
Press release

QED Therapeutics' TRUSELTIQ market size expected to increase many folds by 2032, report DelveInsight

02-19-2024 07:04 AM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

DelveInsight has recently published a report on "TRUSELTIQ Market Forecast Report" providing an in-depth analysis of the TRUSELTIQ market analysis and forecasts up to 2032 in the seven major markets (7MM) (i.e. the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The comprehensive report provides an analysis of TRUSELTIQ market potential and market share analysis in the Cholangiocarcinoma therapeutics space across the 7MM from 2019 to 2032.

The report also helps you to understand the TRUSELTIQ clinical and commercial developments along with parameters like the drug's Mechanism of Action (MOA), Route of Administration (ROA), dosage, and special designations.

Interested in finding out the projected market size of TRUSELTIQ by 2032? Visit: https://www.delveinsight.com/report-store/truseltiq-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

TRUSELTIQ Drug Summary

TRUSELTIQ (infigratinib) is an orally administered FGFR1-3 tyrosine kinase inhibitor in development for the treatment of patients with FGFR-driven diseases, including cholangiocarcinoma (bile duct cancer), urothelial carcinoma (bladder cancer), and achondroplasia. Infigratinib sparingly inhibits FGFR4; patients may tolerate it better than pan-FGFR1-4 inhibitors. QED Therapeutics holds worldwide rights to infigratinib to evaluate its safety and efficacy for multiple FGFR-driven diseases.

The company is also evaluating the product in a phase III clinical study for first-line therapy for cholangiocarcinoma (bile duct cancer) and in a phase II as second-line therapy for cholangiocarcinoma (bile duct cancer). It presented data on infigratinib in cholangiocarcinoma and urothelial carcinoma at the American Society of Clinical Oncology 2020 virtual scientific program.

Dosage and administration
The recommended dosage of TRUSELTIQ is 125 mg (one 100 mg capsule and one 25 mg capsule) taken orally once daily for 21 consecutive days followed by 7 days off therapy, in 28-day cycles. Continue treatment until disease progression or unacceptable toxicity

If a dose of TRUSELTIQ is missed by ≥4 hours or if vomiting occurs, instruct patients to resume the regular daily dose schedule for TRUSELTIQ the next day.

Mechanism of Action
Infigratinib is a small-molecule kinase inhibitor of FGFR with IC50 values of 1.1, 1, 2, and 61 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. The major human metabolites of infigratinib, BHS697 and CQM157, have similar in vitro binding affinities for FGFR1, FGFR2, and FGFR3 compared to infigratinib. Infigratinib inhibited FGFR signaling and decreased cell proliferation in cancer cell lines with activating FGFR amplifications, mutations, or fusions. Constitutive FGFR signaling can support the proliferation and survival of malignant cells. Infigratinib had anti-tumor activity in mouse and rat xenograft models of human tumors with activating FGFR2 or FGFR3 alterations, including two patient-derived xenograft models of cholangiocarcinoma that expressed FGFR2-TTC28 or FGFR2-TRA2B fusions. Infigratinib demonstrated brain-to-plasma concentration ratios (based on AUC0-inf) of 0.682 in rats after a single oral dose.

Stay ahead of the competition by leveraging key insights and evolving trends in the TRUSELTIQ Market @ https://www.delveinsight.com/sample-request/truseltiq-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Highlights of the TRUSELTIQ Market Report

The report contains forecasted sales evaluation of TRUSELTIQ for Cholangiocarcinoma till 2032.
It provides comprehensive coverage of late-stage emerging therapies for Cholangiocarcinoma treatment.
The report also features qualitative and quantitative analysis with analysts, as well as KOL views for TRUSELTIQ in Cholangiocarcinoma.

Why TRUSELTIQ Market Report?
Leading TRUSELTIQ for Cholangiocarcinoma forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the TRUSELTIQ.
A thorough TRUSELTIQ market forecast will help understand how the drug is competing with other emerging therapies in the therapeutics landscape.
It will help to get an analysis of the TRUSELTIQ clinical trial advancements and the detailed clinical assessment, regulatory, and commercial assessment
The report also provides future market assessments for TRUSELTIQ market for Cholangiocarcinoma in the 7 Major Markets, advanced qualitative analysis like SWOT, expert analysts' views, a detailed overview of market competitors, and a short analysis of other emerging therapies in Cholangiocarcinoma.

Request the Sample PDF to Learn More About the Key Offerings of the Report @https://www.delveinsight.com/sample-request/truseltiq-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports By DelveInsight:

Cholangiocarcinoma Market Outlook and Forecast
https://www.delveinsight.com/report-store/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Cholangiocarcinoma Market Insights, Epidemiology and Market Forecast 2032" report delivers an in-depth understanding of Cholangiocarcinoma, historical and forecasted epidemiology as well as the Cholangiocarcinoma market trends in the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan. It also covers the key companies and emerging therapies in the Cholangiocarcinoma therapeutics landscape.

Top Services Offered By DelveInsight:

Elevate healthcare strategies with Delveinsight Healthcare Consulting. Unlock insights, navigate challenges, and drive success in the dynamic healthcare landscape. https://www.delveinsight.com/consulting

Explore success with our case study on R&D, Manufacturing & Commercial Capabilities. Uncover insights for strategic growth in the industry. https://www.delveinsight.com/case-study/r-and-d-landscape-assessment

Unlock success with our Product Assessment case study. Gain valuable insights for strategic decision-making and product optimization in your industry. https://www.delveinsight.com/case-study/oncology-product-assessment-dashboard

Elevate your business with our Market Assessment case study. Transform insights into strategic actions for success in your industry. https://www.delveinsight.com/case-study/immune-checkpoint-inhibitor-market-potential

428, Corporate Park, Sector-21, Dwarka,
New Delhi-110077, India

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release QED Therapeutics' TRUSELTIQ market size expected to increase many folds by 2032, report DelveInsight here

News-ID: 3388700 • Views:

More Releases from DelveInsight Business Research LLP

Erectile Dysfunction Devices Market Outlook Report 2032 by DelveInsight Exploring Market Drivers, Key Growth Challenges, Technological Advancements, and Future Market Potential
Erectile Dysfunction Devices Market Outlook Report 2032 by DelveInsight Explorin …
DelveInsight's Erectile Dysfunction Devices Market Insights Report 2032 provides the current and forecast market analysis, individual leading Erectile Dysfunction Devices Companies market shares, challenges, Erectile Dysfunction Devices Market Drivers, barriers, trends, and key market Erectile Dysfunction Devices companies in the market. To read more about the latest highlights related to the Erectile Dysfunction Devices Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/erectile-dysfunction-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key
Structural Heart Devices Market Size Report 2032: DelveInsight Report on Demand Surge, Clinical Effectiveness, Technological Progress, and Global Market Growth Trajectory
Structural Heart Devices Market Size Report 2032: DelveInsight Report on Demand …
DelveInsight's Structural Heart Devices Market Insights Report 2032 provides the current and forecast market analysis, individual leading Structural Heart Devices Companies market shares, challenges, Structural Heart Devices Market Drivers, barriers, trends, and key market Structural Heart Devices companies in the market. To read more about the latest highlights related to the Structural Heart Devices Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/structural-heart-devices-market-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key Takeaways
DelveInsight's Urolithiasis Management Devices Market 2032 Report Offering In-Depth Insights into Market Segmentation, Regional Landscape, Pipeline Products, and Growth Outlook
DelveInsight's Urolithiasis Management Devices Market 2032 Report Offering In-De …
DelveInsight's Urolithiasis Management Devices Market Insights Report 2032 provides the current and forecast market analysis, individual leading Urolithiasis Management Devices Companies market shares, challenges, Urolithiasis Management Devices Market Drivers, barriers, trends, and key market Urolithiasis Management Devices companies in the market. To read more about the latest highlights related to the Urolithiasis Management Devices Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/urolithiasis-management-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key Takeaways
Transradial Access Products Market Forecast Report 2032 by DelveInsight Featuring Market Trends, Strategic Collaborations, Innovation Landscape, and Long-Term Growth Prospects
Transradial Access Products Market Forecast Report 2032 by DelveInsight Featurin …
DelveInsight's Transradial Access Products Market Insights Report 2032 provides the current and forecast market analysis, individual leading Transradial Access Products Companies market shares, challenges, Transradial Access Products Market Drivers, barriers, trends, and key market Transradial Access Products companies in the market. To read more about the latest highlights related to the Transradial Access Products Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/transradial-access-products-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Key Takeaways

All 5 Releases


More Releases for TRUSELTIQ

Intrahepatic Cholangiocarcinoma Pipeline Insight 2025: 20+ Emerging Therapies Ta …
ChatGPT said: The intrahepatic cholangiocarcinoma (iCCA) pipeline is growing steadily, with over 18 companies focused on targeted and immunotherapeutic strategies. Key advances include FGFR2 fusions, IDH1/2 mutations, and HER2 amplifications, driving precision oncology in this aggressive liver cancer. Approvals of FGFR inhibitors like Pemazyre and Truseltiq have advanced biomarker-driven second-line treatments. DelveInsight's "Intrahepatic Cholangiocarcinoma - Pipeline Insight, 2025 [https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]" provides a detailed analysis of the therapeutic development landscape for iCCA, a
Bile Duct Cancer Market Insights, Epidemiology, and Market Forecast 2032 Report …
The market size of Bile Duct Cancer is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Servier, Genfit, TransThera Sciences (Nanjing), Inc., Incyte Corporation, Innovent Biologics (Suzhou) Co. Ltd., Ze-yang Ding, MD. [Nevada, United States] - DelveInsight, a leading market research company, is excited to introduce its newest report, titled "Bile Duct Cancer Market Insights, Epidemiology,
Cholangiocarcinoma Market Size was USD 786.1 million in 2021
The Cholangiocarcinoma Market is expected to show positive growth attributed to the increased diagnosed prevalence and also, the launch of upcoming devices during the forecast period. Moreover, advances in disease mechanisms have yielded new diagnostic and treatment approaches, opening avenues to better treatment interventions. The Cholangiocarcinoma market report provides current treatment practices, emerging drugs, Cholangiocarcinoma market share of the individual therapies, current and forecasted Cholangiocarcinoma market Size from 2019 to 2032
Cholangiocarcinoma Market Size was USD 786.1 Million in 2021
"The increase in Cholangiocarcinoma market size is a direct consequence of increasing incident population of Cholangiocarcinoma, an increase in investment in the R&D of drugs leading to a rich pipeline in the 7MM" The Cholangiocarcinoma market report provides current treatment practices, emerging drugs, cholangiocarcinoma market share of the individual therapies, current and forecasted cholangiocarcinoma market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current cholangiocarcinoma
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight
Global Fibroblast Growth Factor Receptor FGFR Cancer Therapy Market Clinical Tri …
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026 Report Highlights: • Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 • Role of FGFR Inhibitors in Cancer Therapy • Global FGFR Market Assessment (US$) by Region and Cancer Type • Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) • Dosage and Drug Price Insight on Approved FGFR Inhibitors • Comprehensive Clinical Trials Insight by Company, Country, Phase and